Pfizer Inc has received the U.S. Food and Drug Administration (FDA) approval for TOVIAZ™ (fesoterodine fumarate) extended release tablets for the treatment of overactive bladder (OAB) symptoms.
New once-daily TOVIAZ can significantly reduce the number of urge urinary incontinence episodes and the frequency of urination over 24 hours, symptoms of OAB that can significantly impact patients’ lives. Overactive bladder is a bothersome medical condition that affects an estimated one in six Americans, yet still remains highly undertreated. TOVIAZ is currently available in Europe.
Structurally related to the most prescribed OAB medication, Pfizer’s Detrol® LA (tolterodine tartrate extended release capsules), TOVIAZ can help regulate the involuntary contractions of the bladder associated with OAB. These contractions cause frequent, sudden urges to urinate. The two efficacious and well-tolerated doses of TOVIAZ, 4 mg and 8 mg, allow dosing flexibility to optimize treatment based on the individual patient response and tolerability.
“The emotional and social implications for people who suffer from OAB are challenging, yet the condition remains underdiagnosed and highly undertreated,” said Nancy Muller, executive director, National Association For Continence. “We need to encourage people with OAB symptoms to stop simply coping and start talking to their doctors about finding treatment approaches that work for them. New treatments, like TOVIAZ, offer healthcare professionals another option to help their patients.” TOVIAZ will be available in the United States in the first half of 2009.